Article

Health-Related Quality-of-Life Outcomes in Patients Treated with Push-Pull OROS Hydromorphone versus Extended-Release Oxycodone for Chronic Hip or Knee Osteoarthritis Pain: A Randomized, Open-Label, Parallel-Group, Multicenter Study.

1 Abt Bio-Pharma Solutions, Incorporated, Lexington, Massachusetts, USA 2 QualityMetric Incorporated, Lincoln, Rhode Island, USA 3 Ortho-McNeil Janssen Scientific Affairs, LLC, Raritan, New Jersey, USA 4 Janssen Pharmaceutica, Beerse, Belgium 5 Patient Value Solutions, Huldenberg, Belgium.
The patient (impact factor: 0.57). 07/2008; 1(3):223-38. DOI:10.2165/1312067-200801030-00009 pp.223-38
Source: PubMed

ABSTRACT Chronic osteoarthritis (OA) pain impacts health-related quality of life (HR-QOL).
The primary aim of this study was to evaluate and compare HR-QOL outcomes following treatment with once-daily push-pull Osmotic controlled-Release Oral delivery System (OROS) hydromorphone versus twice-daily extended-release (ER) oxycodone for moderate to severe chronic knee or hip OA pain.
This was a 6-week, randomized, open-label, parallel-group, multicenter study of 124 patients with OA whose pre-trial treatment included NSAIDs or other non-steroidal, non-opioid analgesics. The HR-QOL of patients was assessed using the Medical Outcomes Study (MOS) Sleep Scale and the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC™). Within- and between-group changes from baseline to 6 weeks were evaluated using ANOVA.
At baseline, trial patients had significantly worse MOS Sleep Scale (multivariate ANOVA [MANOVA] F = 11.0, p < 0.001) and WOMAC™ scores (MANOVA F = 55.7, p < 0.001) than chronic disease benchmarks. Both treatment groups showed significant improvements on the sleep disturbance scale (p < 0.01), with additional improvements observed with OROS hydromorphone on the sleep quantity (p = 0.046), sleep snoring (p = 0.044), awaken short of breath or with a headache (p = 0.024), 6-item sleep problems index I (p < 0.001), and 9-item sleep problems index II (p < 0.001) scales. Significant treatment differences in favor of OROS hydromorphone over ER oxycodone were also observed on the awaken short of breath or with a headache (p = 0.014) scale and sleep problems index I (p = 0.045). Both treatment groups showed comparable large effect size (>0.8 SD unit) improvements on the WOMAC™ scale (measuring functionality outcomes such as pain, stiffness, physical function etc).
Both OROS hydromorphone and ER oxycodone improved sleep and function, with greater sleep benefits being observed in patients treated with OROS hydromorphone.

0 0
 · 
0 Bookmarks
 · 
13 Views
  • Source
    Article: Controlled release formulation of oxycodone in patients with moderate to severe chronic osteoarthritis: a critical review of the literature.
    Robert Taylor, Robert B Raffa, Joseph V Pergolizzi
    [show abstract] [hide abstract]
    ABSTRACT: Osteoarthritis (OA) is a physically and emotionally debilitating disease that predominantly affects the aging adult population. Current pharmacologic treatment options primarily consist of nonsteroidal anti-inflammatory drugs and/or acetaminophen, but associated side effects, analgesic limitations, especially in the elderly, and the need for around-the-clock analgesia have led physicians to search for alternative analgesics. Opioids have shown effectiveness at mitigating both chronic cancer and noncancer pain, and their ability to be placed into controlled release (CR) formulations suggests that they may prove efficacious for OA patients. One formulation, oxycodone CR, has shown effectiveness in cancer pain patients and in some trials of noncancer low back pain. In this review, the objective was to synthesize the reported findings by researchers in this field and present an up-to-date look at the efficacy, safety, and tolerability of oxycodone CR in OA patients. Public literature databases were searched using specific keywords (eg, oxycodone CR) for studies assessing the efficacy and safety profile of oxycodone CR and its use in patients with OA. A total of eleven articles that matched the criteria were identified, which included three placebo-controlled trials, six comparative trials, one pharmacokinetic study in the elderly, and one long-term safety trial. Analysis of the studies revealed that oxycodone CR is reasonably efficacious, safe, and tolerable when used to manage moderate to severe chronic OA pain, with similar side effects to that of other opioids.
    Journal of Pain Research 01/2012; 5:77-87.
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

6-week
 
additional improvements
 
chronic disease benchmarks
 
Chronic osteoarthritis
 
comparable large effect size
 
hip OA pain
 
McMaster Universities Osteoarthritis Index
 
Medical Outcomes Study
 
multicenter study
 
non-opioid analgesics
 
pre-trial treatment
 
problems index
 
problems index II
 
severe chronic knee
 
significant improvements
 
Significant treatment differences
 
sleep disturbance scale
 
treatment groups
 
trial patients
 
Western Ontario